New tests could transform care for rare kidney diseases
NCT ID NCT05985122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers to find markers that help classify the disease and guide treatment. The goal is to make diagnosis more accurate and personalize care with existing or new drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Ranica, BG, 24020, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test